Elise A Olsen MDProfessor of Dermatology and Medicine, Duke University School of Medicine; Director, Cutaneous Lymphoma Research and Treatment Center; Director, Hair Disorders Research and Treatment Center; Director, Dermatopharmacology Study Center, Duke University Medical Center, Durham, North Carolina
Dr. Olsen is Professor of Dermatology and Medicine (Oncology) at Duke University and the founder and Director of the Duke Cutaneous Lymphoma Research and Treatment Center. She is a past President, Secretary-Treasurer and Director of the International Society for Cutaneous Lymphomas (ISCL) and created the ISCL website, cutaneouslymphoma.org. She is first author on the consensus revisions to the staging and classification of mycosis fungoides (MF) and Sézary Syndrome (SS) (published in Blood 2007) and first author on the consensus endpoints and response criteria for MF and SS that evolved from 8 meetings she chaired on this topic (published in JCO 2011). She is co-author on the guidelines for staging and classification of non-MF/SS types of CTCL (also published in Blood 2007) and first author on the clinical trials guidelines submitted for publication. She organized and chaired the only “Think Tank on CTCL” that involved academicians, industry and the FDA. She was one of 3 dermatologists involved in the development of the NCCN guidelines for MF and SS and remains a consultant on cutaneous lymphoma for the NHL group of NCCN. She is a founder and immediate pasat President of the newly formed multidisciplinary society, the United States Cutaneous Lymphoma Consortium (USCLC) and is Chairman of the new national registry project for cutaneous lymphomas that is a key goal of this group. She is first author on the USCLC consensus guidelines on Sézary syndrome (published in JAAD 2011) and the first author of USCLC consensus guidelines for the use of phototherapy in MF/SS (in final preparation). She is part of a national group evaluating cytotoxic cutaneous lymphomas and recently chaired a USCLC workshop documenting the US experience of bone marrow transplant in MF/SS. She is founder and Director of the Duke Dermatopharmacology Study Center and has been principle investigator on more than 160 clinical trials, many on CTCL. She was the first author on the publications summarizing the approval trials of denileukin diftitox (Ontak) and vorinostat (Zolinza) (both JCO publications). Dr. Olsen was invited to give the annual Litchfield Lecture in Oxford, Great Britain in September 2010 on cutaneous lymphomas.
Dr. Olsen is also the founder and Director of the Duke University Hair Disorders Research and Treatment Center. She serves as a referral source for patients with hair disorders from all over the United States as well as internationally. Dr. Olsen is one of the founders, past President and past Board member of the North American Hair Research Society (NAHRS) and currently serves as Chairman of the NAHRS Website Committee. She is the Co-Chairman of the Hair section of the international "Faculty of 1000" online information resource for physicians. She is the author of the first and second editions of the textbook, "Hair Disorders: Diagnosis and Treatment” and has written the clinical hair sections for major general and pediatric dermatology textbooks. She is on the Scientific Advisory Board of the National Alopecia Areata Foundation and served as Chairman of the NAAF taskforce to develop investigative guidelines for alopecia areata. She has also chaired consensus guidelines for the classification, evaluation and treatment of pattern hair loss. She is currently the lead investigator on multicenter trials of hair loss in African Americans and a scarring hair loss condition called frontal fibrosing alopecia and has developed new guidelines for the assessment of chemotherapy related hair loss both for the Multinational Association of Supportive Care in Cancer (MASCC) and the NCI CTCAE V4.0. She was the invited keynote speaker at the Australasian College of Dermatologists Annual Meeting in 2007 on hair disorders.
Dr. Olsen is the current Vice-President of the American Academy of Dermatology (AAD), one of two nominees for President-Elect, immediate past Chairman of the Patient Advocacy Task Force and member of the AAD Council for Science and Research, Strategic Alliance Liaison Committee, Priorities Committee, Cutaneous Oncology Task Force, Data Collection Work Group, Registries Committee, Intersociety Liaison Committee, Advisory Board and Budget Committee. She has served on the AAD Board of Directors, the FDA Liaison Task Force, the Guidelines of Care Task Force, the Membership Committee, the Scientific Awards Committee, the Named Lectureship Task Force, Young Investigator Award Task Force, Grassroots Advocacy Committee and as an Assistant Editor of the Journal of the American Academy of Dermatology, the latter for 10 years. Dr. Olsen is a Founder and first President of the NC Dermatology Association and past President-Elect, Secretary-Treasurer and Delegate for the Dermatology Section of the North Carolina Medical Society. She is the Chairman of the Steering Committee of the “Southeastern Consortium for Dermatology" (an association of 10 academic institutions), Associate Editor of the journal "Dermatologic Therapy", and is on the 5 member Duke University committee that reviews potential misconduct in research across the University. She is a member of the Duke Clinical Research Institute. She is a past Vice-President, Secretary, Corresponding Secretary, Parlimentarian and Co-Chairman of the Academic Dermatology Committee of the Women’s Dermatologic Society (WDS). She is a past member of the Board of Directors of the Leaders' Society of the Dermatology Foundation.